|The window of therapeutic opportunity in multiple sclerosis|
AJ Coles, A Cox, E Le Page, J Jones, SA Trip, J Deans, S Seaman, ...
Journal of neurology 253 (1), 98-108, 2006
|IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)|
JL Jones, CL Phuah, AL Cox, SA Thompson, M Ban, J Shawcross, ...
The Journal of clinical investigation 119 (7), 2052-2061, 2009
|Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis|
AL Cox, SAJ Thompson, JL Jones, VH Robertson, G Hale, H Waldmann, ...
European journal of immunology 35 (11), 3332-3342, 2005
|Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis|
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
|Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy|
O Tuohy, L Costelloe, G Hill-Cawthorne, I Bjornson, K Harding, ...
Journal of Neurology, Neurosurgery & Psychiatry 86 (2), 208-215, 2015
|Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort|
M Cossburn, AA Pace, J Jones, R Ali, G Ingram, K Baker, C Hirst, ...
Neurology 77 (6), 573-579, 2011
|B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis|
SAJ Thompson, JL Jones, AL Cox, DAS Compston, AJ Coles
Journal of clinical immunology 30 (1), 99-105, 2010
|Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation|
JL Jones, SAJ Thompson, P Loh, JL Davies, OC Tuohy, AJ Curry, ...
Proceedings of the National Academy of Sciences 110 (50), 20200-20205, 2013
|Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple …|
SV Abrahamsson, DF Angelini, AN Dubinsky, E Morel, U Oh, JL Jones, ...
Brain 136 (9), 2888-2903, 2013
|Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis|
GA Hill-Cawthorne, T Button, O Tuohy, JL Jones, K May, J Somerfield, ...
Journal of Neurology, Neurosurgery & Psychiatry 83 (3), 298-304, 2012
|Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity|
JL Jones, JM Anderson, CL Phuah, EJ Fox, K Selmaj, D Margolin, ...
Brain 133 (8), 2232-2247, 2010
|Alemtuzumab vs. interferon beta-1a in early multiple sclerosis|
CAMMS223 Trial Investigators
N Engl J Med 359, 1786-1801, 2008
|Immune competence after alemtuzumab treatment of multiple sclerosis|
CL McCarthy, O Tuohy, DAS Compston, DS Kumararatne, AJ Coles, ...
Neurology 81 (10), 872-876, 2013
|Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes|
MS Zandi, RW Paterson, MA Ellul, L Jacobson, A Al-Diwani, JL Jones, ...
Journal of Neurology, Neurosurgery & Psychiatry 86 (7), 708-713, 2015
|Distinct microbial and immune niches of the human colon|
KR James, T Gomes, R Elmentaite, N Kumar, EL Gulliver, HW King, ...
Nature Immunology 21 (3), 343-353, 2020
|Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis|
L Costelloe, J Jones, A Coles
Expert review of neurotherapeutics 12 (3), 335-341, 2012
|Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy|
EA Marsh, CL Hirst, JG Llewelyn, MD Cossburn, MM Reilly, A Krishnan, ...
Journal of neurology 257 (6), 913-919, 2010
|Oligodendrocyte susceptibility to injury by T-cell perforin.|
NJ Scolding, J Jones, DA Compston, BP Morgan
Immunology 70 (1), 6, 1990
|The immunological response to traumatic brain injury|
EJ Needham, A Helmy, ER Zanier, JL Jones, AJ Coles, DK Menon
Journal of neuroimmunology 332, 112-125, 2019
|A novel strategy to reduce the immunogenicity of biological therapies|
J Somerfield, GA Hill-Cawthorne, A Lin, MS Zandi, C McCarthy, JL Jones, ...
The Journal of Immunology 185 (1), 763-768, 2010